ArticleJPGN reports2026
Severe allergic reaction to ustekinumab reinitiation in a pediatric patient with Crohn's disease: A case report.
Article in JPGN reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ustekinumab (UST) is a monoclonal antibody used in the management of moderate to severe inflammatory bowel disease. While generally well-tolerated, serious adverse reactions, including hypersensitivity and anaphylaxis, have been documented, specifical following the initial intravenous (IV) dose. There is limited literature on hypersensitivity reactions in pediatric patients, particularly after re-induction with IV therapy. This case highlights a novel, previously unreported scenario of a severe allergic reaction in a 10-year-old female with Crohn's disease (CD) during her second, re-induction IV dose of UST, despite prior tolerance and no detectable UST antibodies. This case emphasizes the need for continued monitoring during IV UST administration, even in patients with prior tolerability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.